Natco Pharma Limited increased its investment in US-based biotechnology firm eGenesis, Inc. to $16.70 million. This follows a previous commitment of $14.00 million through its global subsidiaries.
Natco Pharma Limited's subsidiaries will invest Rs 134.01 Crore in eGenesis, Inc., a US-based biotechnology company. The investment involves subscribing to 8% convertible promissory notes.
NATCO Pharma Limited is investing US$ 14 million (approx. ₹133 Crore) in eGenesis, Inc. via convertible promissory notes. This increases NATCO's total investment in the biotechnology firm to US$ 22 million.
